Core Viewpoint - 康哲药业's subsidiary 德镁医药 is seeking independent listing on the Hong Kong Stock Exchange and has received approval for clinical trials of povorcitinib for specific skin conditions [1] Group 1: Company Developments - 德镁医药 has been granted a clinical trial approval notice by the National Medical Products Administration (NMPA) of China on August 27, 2025, for povorcitinib [1] - The clinical trials will focus on the treatment of non-segmental vitiligo and moderate to severe hidradenitis suppurativa (HS) [1] Group 2: Product Information - Povorcitinib is a selective oral small molecule JAK1 inhibitor, with substance and use patents in specific countries/regions [1] - The drug is currently undergoing Phase 3 clinical trials for non-segmental vitiligo, HS, and nodular prurigo in several overseas countries, along with Phase 2 trials for asthma and chronic spontaneous urticaria [1]
康哲药业(00867)：创新药口服小分子JAK1抑制剂Povorcitinib获得白癜风、化脓性汗腺炎适应症药物临床试验批准通知书